HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?
Mafham M, Preiss D
The Lancet. Pub. online October 2, 2018
Leggi
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Frias JP, Nauck MA, Van J, et al.
The Lancet. Pub. online October 4, 2018
Leggi
Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial
Bohula EA, Scirica BM, Inzucchi SE, et al.
The Lancet. Pub. online October 4, 2018
Leggi
Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial
Tauschmann M, Thabit H, Bally L, et al.
The Lancet. Pub. online October 3, 2018
Leggi
Enlarging the loop: closed-loop insulin delivery for type 1 diabetes
Galderisi A, Sherr JL
The Lancet. Pub. online October 3, 2018
Leggi
Comparison of Medical Care Utilization and Costs Among Patients with Statin-Controlled Low-Density Lipoprotein Cholesterol With Versus Without Hypertriglyceridemia
Nichols GA, Philip S, Reynolds K, et al.
Am J Cardiol 2018; 122(7):1128-32
Leggi
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Hernandez AF, Green JB, Janmohamed S, et al.
The Lancet. Pub. online October 2, 2018
Leggi
Glucose lowering and the kidney: are all drug classes equal?
Wong MG, Jardine M, Perkovic V
Lancet Diabetes Endocrinol. Pub. online October 3, 2018
Leggi
Comparison of Frequency of Atherosclerotic Cardiovascular and Safety Events with Systolic Blood Pressure <120 mm Hg Versus 135-139 mm Hg in a Systolic Blood Pressure Intervention Trial Primary Prevention Subgroup
Plante TB, Juraschek SP, Miller III ER, et al.
Am J Cardiol 2018; 122(7):1185-90
Leggi
Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
Muskiet MHA, Tonneijck L, Huang Y, et al.
Lancet Diabetes Endocrinol. Pub. online October 3, 2018
Leggi